IRCT2017070834945N1招募中2 期
Evaluation of resectability rate and tumor complete pathological response in patients with locally advanced proximal gastric cancers receiving neoadjuant chemoradiothrapy
Vice-chancellery for Research and Technology, Mashhad University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •performance status 0, 1 and 2; surgery in future treatment planning; and good condition for chemotherapy, radiotherapy and surgery.
- •Exclusion criteria: metastasis; death.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
eoadjuvant chemoradiotheraphy in patients with locally advanced gastric cancerCondition 1: Proximal gastric cancer. Condition 2: Gastro-oesophageal cancer.Fundus of stomachGastro-oesophagea cancerlIRCT2014072015044N1Vice chancellor for research, Mashhad University of Medical Sciences30
进行中（未招募）
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CR-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialEUCTR2005-005139-84-ATPIERRE FABRE MEDICAMENT200
进行中（未招募）
不适用
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialocally advanced non small cell lung cancerEUCTR2005-005139-84-CZPIERRE FABRE MEDICAMENT200
进行中（未招募）
1 期
Evaluation of the rate of pathological complete response rate (pCR) for neoadjuvant chemoradiotherapy (CT-RT) and for chemotherapy (CT) alone in locally advanced non small cell lung cancer (LA-NSCLC): a randomised phase II trialocally advanced non small cell lung cancerMedDRA version: 8.1Level: LLTClassification code 10025044Term: Lung cancerEUCTR2005-005139-84-FIPIERRE FABRE MEDICAMENT200
招募中
不适用
Evaluation of cytology-based tumor resection for the surgical treatment of head and neck squamous cell carcinoma (HNSCC) patientsC06.9C10.9Mouth, unspecifiedOropharynx, unspecifiedDRKS00013507niversitätsklinikum des SaarlandesKlinik für HNO-Heilkunde50